Cargando…

Indole alkaloids as potential candidates against COVID-19: an in silico study

COVID-19 has recently grown to be pandemic all around the world. Therefore, efforts to find effective drugs for the treatment of COVID-19 are needed to improve humans’ life quality and survival. Since the main protease (M(pro)) of SARS-CoV-2 plays a crucial role in viral replication and transcriptio...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohseni, Mehran, Bahrami, Hamed, Farajmand, Bahman, Hosseini, Faezeh Sadat, Amanlou, Massoud, Salehabadi, Hafezeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094126/
https://www.ncbi.nlm.nih.gov/pubmed/35546368
http://dx.doi.org/10.1007/s00894-022-05137-4
Descripción
Sumario:COVID-19 has recently grown to be pandemic all around the world. Therefore, efforts to find effective drugs for the treatment of COVID-19 are needed to improve humans’ life quality and survival. Since the main protease (M(pro)) of SARS-CoV-2 plays a crucial role in viral replication and transcription, the inhibition of this enzyme could be a promising and challenging therapeutic target to fight COVID-19. The present study aims to identify alkaloid compounds as new potential inhibitors for SARS-CoV-2 M(pro) by the hybrid modeling analyses. The docking-based virtual screening method assessed a collection of alkaloids extracted from over 500 medicinal plants and sponges. In order to validate the docking process, classical molecular dynamic simulations were applied on selected ligands, and the calculation of binding free energy was performed. Based on the proper interactions with the active site of the SARS-CoV-2 M(pro), low binding energy, few side effects, and the availability in the medicinal market, two indole alkaloids were found to be potential lead compounds that may serve as therapeutic options to treat COVID-19. This study paves the way for developing natural alkaloids as stronger potent antiviral agents against the SARS-CoV-2. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00894-022-05137-4.